Other Reports

Haney M, Hill MN. Cannabis and Cannabinoids: From Synapse to Society. Neuropsychopharmacology. 2018 Jan;43(1):1-3. doi: 10.1038/npp.2017.255.

Busquets-Garcia A, Bains J, Marsicano G. CB(1) Receptor Signaling in the Brain: Extracting Specificity from Ubiquity. Neuropsychopharmacology. 2018 Jan;43(1):4-20. doi: 10.1038/npp.2017.206. Epub 2017 Sep 1.

Meyer HC, Lee FS, Gee DG. The Role of the Endocannabinoid System and Genetic Variation in Adolescent Brain Development. Neuropsychopharmacology. 2018 Jan;43(1):21-33. doi: 10.1038/npp.2017.143. Epub 2017 Jul 7.

Cooper ZD, Craft RM. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology. 2018 Jan;43(1):34-51. doi: 10.1038/npp.2017.140. Epub 2017 Jul 17.

Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH. The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology. 2018 Jan;43(1):52-79. doi: 10.1038/npp.2017.204. Epub 2017 Aug 31.

Hill MN, Campolongo P, Yehuda R, Patel S. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology. 2018 Jan;43(1):80-102. doi: 10.1038/npp.2017.162. Epub 2017 Jul 26.

Wenzel JM, Cheer JF. Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling. Neuropsychopharmacology. 2018 Jan;43(1):103-115. doi: 10.1038/npp.2017.126. Epub 2017 Jun 27.

Panlilio LV, Justinova Z. Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure. Neuropsychopharmacology. 2018 Jan;43(1):116-141. doi: 10.1038/npp.2017.193. Epub 2017 Aug 28.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ(9)-Tetrahydrocannabinol. Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6.

Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going? Neuropsychopharmacology. 2018 Jan;43(1):155-172. doi: 10.1038/npp.2017.130. Epub 2017 Jun 27.

Brezing CA, Levin FR. The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal. Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6. Review.

Hasin DS. US Epidemiology of Cannabis Use and Associated Problems. Neuropsychopharmacology. 2018 Jan;43(1):195-212. doi: 10.1038/npp.2017.198. Epub 2017 Aug 30.

McLaughlin RJ. Toward a Translationally Relevant Preclinical Model of Cannabis Use. Neuropsychopharmacology. 2018 Jan;43(1):213. doi: 10.1038/npp.2017.191.

Haines-Saah RJ, Jenkins EK. Setting the Legal Age for Access to Cannabis in Canada: Bridging Neuroscience, Policy, and Prevention. Neuropsychopharmacology. 2018 Jan;43(1):213-214. doi: 10.1038/npp.2017.234.

Ware MA. Medical Cannabis Research: Issues and Priorities. Neuropsychopharmacology. 2018 Jan;43(1):214-215. doi: 10.1038/npp.2017.222.

Watts VJ. Selective Adenylyl Cyclase Type 1 Inhibitors as Potential Opioid Alternatives For Chronic Pain. Neuropsychopharmacology. 2018 Jan;43(1):215-216. doi: 10.1038/npp.2017.190.

Baumann MH, Pasternak GW. Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg? Neuropsychopharmacology. 2018 Jan;43(1):216-217. doi: 10.1038/npp.2017.211.

Nummenmaa L, Karjalainen T. Opioidergic regulation of pain and pleasure in human social relationships. Neuropsychopharmacology. 2018 Jan;43(1):217-218. doi: 10.1038/npp.2017.200.

Zheng J, Lin JJ. Modulating Amygdala-Hippocampal Network Communication: A Potential Therapy for Neuropsychiatric Disorders. Neuropsychopharmacology. 2018 Jan;43(1):218-219. doi: 10.1038/npp.2017.201.

Bury LA, Wynshaw-Boris A. Modeling Non-Syndromic Autism with Human-Induced Pluripotent Stem Cells. Neuropsychopharmacology. 2018 Jan;43(1):219-220. doi: 10.1038/npp.2017.195.

Moeller FG, Cunningham KA. Innovative Therapeutic Intervention For Opioid Use Disorder. Neuropsychopharmacology. 2018 Jan;43(1):220-221. doi: 10.1038/npp.2017.192.

Kavalali ET, Monteggia LM. The Ketamine Metabolite 2R,6R-Hydroxynorketamine Blocks NMDA Receptors and Impacts Downstream Signaling Linked to Antidepressant Effects. Neuropsychopharmacology. 2018 Jan;43(1):221-222. doi: 10.1038/npp.2017.210.

Wagner MJ. Cognitive Signaling in Cerebellar Granule Cells. Neuropsychopharmacology. 2018 Jan;43(1):222-223. doi: 10.1038/npp.2017.186.

Caligiuri SP, Kenny PJ. The Promise of Genome Editing for Modeling Psychiatric Disorders. Neuropsychopharmacology. 2018 Jan;43(1):223-224. doi: 10.1038/npp.2017.197.

Golden SA, Shaham Y. Aggression Addiction and Relapse: A New Frontier in Psychiatry. Neuropsychopharmacology. 2018 Jan;43(1):224-225. doi: 10.1038/npp.2017.173.

Corcoran CM, Cecchi GA. Computational Approaches to Behavior Analysis in Psychiatry. Neuropsychopharmacology. 2018 Jan;43(1):225-226. doi: 10.1038/npp.2017.188.

Shekhar A, Thakur GA. Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder. Neuropsychopharmacology. 2018 Jan;43(1):226-227. doi: 10.1038/npp.2017.230.

Cattaneo A, Pariante CM. Integrating 'Omics' Approaches to Prioritize New Pathogenetic Mechanisms for Mental Disorders. Neuropsychopharmacology. 2018 Jan;43(1):227-228. doi: 10.1038/npp.2017.221.

Joyner MA, Gearhardt AN, Flagel SB. A Translational Model to Assess Sign-Tracking and Goal-Tracking Behavior in Children. Neuropsychopharmacology. 2018 Jan;43(1):228-229. doi: 10.1038/npp.2017.196.

Baytaş O, Morrow EM. The Role of Mitochondrial Glutamate Metabolism in Cognitive Development and Disease. Neuropsychopharmacology. 2018 Jan;43(1):229-230. doi: 10.1038/npp.2017.202.

Young JW, Light GA. Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap. Neuropsychopharmacology. 2018 Jan;43(1):230-231. doi: 10.1038/npp.2017.218.

Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S, Wall MM. US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017 Apr 26. doi: 10.1001/jamapsychiatry.2017.0724. [Epub ahead of print]

Colorado Department of Revenue. Marijuana Equivalency in Portion and Dosage. August 10, 2015.

Kaskie B, Ayyagari P, Milavetz G, Shane D, Arora K. The Increasing Use of Cannabis Among Older Americans: A Public Health Crisis or Viable Policy Alternative? Gerontologist. 2017 Jan 11. pii: gnw166. doi: 10.1093/geront/gnw166. [Epub ahead of print]

National Academies Press. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017). ISBN: 978-0-309-45304-2. DOI: 10.17226/24625

Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016 May;17(5):293-306. doi: 10.1038/nrn.2016.28. Epub 2016 Apr 7.

AAA Foundation for Traffic Safety. An Evaluation of Data from Drivers Arrested for Driving Under the Influence in Relation to Per se Limits for Cannabis. May, 2016.

AAA Foundation for Traffic Safety. Prevalence of Marijuana Involvement in Fatal Crashes: Washington, 2010 - 2014. May, 2016.

Federation of State Medical Boards. Model Guidelines for the Recommendation of Marijuana in Patient Care. April, 2016.

World Health Organization (WHO). The health and social effects of nonmedical cannabis use. 2016.

Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016 Feb 16. doi: 10.1111/add.13347.

Piomelli D, Grant I. Medicinal Cannabis in California: an interview with Igor Grant, MD. Cannabis and Cannabinoid Research 1:1, 78–80, DOI: 10.1089/can.2016.29005.igr.

Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA. Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA. 2016 Feb 2;113(5):E500-8. doi: 10.1073/pnas.1516648113. Epub 2016 Jan 19.

Wong K & Clarke C. (2015, September). The Legalization of Marijuana in Colorado: The Impact. Rocky Mountain High Intensity Drug Trafficking Area.

Compton, R. P. & Berning, A. (2015, February). Drug and alcohol crash risk. (Traffic Safety Facts Research Note. DOT HS 812 117). Washington, DC: National Highway Traffic Safety Administration.

Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE. Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci. 2015 Jan 28;35(4):1505-12. doi: 10.1523/JNEUROSCI.2946-14.2015.

American Academy of Pediatrics, Policy Statement. The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics. 2015 Jan 26. pii: peds. 2014-4147.

American Academy of Pediatrics, Technical Report. The Impact of Marijuana Policies on Youth: Clinical, Research, and Legal Update. Pediatrics. 2015 Jan 26. pii: peds. 2014-4146.

Power RA, Verweij KJ, Zuhair M, Montgomery GW, Henders AK, Heath AC, Madden PA, Medland SE, Wray NR, Martin NG. Genetic predisposition to schizophrenia associated with increased use of cannabis. Mol Psychiatry. 2014 Nov;19(11):1201-4. doi: 10.1038/mp.2014.51. Epub 2014 Jun 24.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Apr 29;82(17):1556-63.

Molina PE, Amedee AM, Lecapitaine NJ, Zabaleta J, Mohan M, Winsauer PJ, Vande Stouwe C, McGoey RR, Auten MW, Lamotte L, Chandra LC, Birke LL. Modulation of Gut-Specific Mechanisms by Chronic Δ9-Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis. AIDS Res Hum Retroviruses. 2014 Feb 7.

Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.

Sirven JI. Medical marijuana for epilepsy: Winds of change. Epilepsy Behav. 2013 Dec;29(3):435-6. doi: 10.1016/j.yebeh.2013.09.004.

Cooper ZD, Comer SD, Haney M. Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana In Daily Marijuana Smokers. Neuropsychopharmacology. 2013 Apr 22. doi: 10.1038/npp.2013.97.

Schier AR, Ribeiro NP, de Oliveira e Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012 Jun;34 Suppl 1:S104-10. English, Portuguese.

Abrams DA, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-Opioid Interaction in Chronic Pain. Clinical Pharmacology & Therapeutics (2011); 90 6, 844–851. doi:10.1038/clpt.2011.188.

California Medical Association. Cannabis and the Regulatory Void: Background Paper and Recommendations. (2011)

American Society of Addiction Medicine, President’s Action Committee on Medical Marijuana. The Role of the Physician in "Medical" Marijuana. Barthwell A., Baxter L., Cermak T., DuPont R., Kraus M., Levounis P. September 2010.

Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 10.1503/cmaj.091414. August 2010.

Center for Medicinal Cannabis Research: Report to the California Legislature (2010)

American Medical Association, Report 3 of the Council on Science and Public Health, Use of Cannabis for Medicinal Purposes (2009)

American College of Physicians, Position Paper: Supporting Research into the Therapeutic Role of Marijuana (2008)

Action Report: Medical Board of California, July 2004. California Physicians & Medical Marijuana: A Statement by the Medical Board of California -- May 7, 2004

National Institute on Drug Abuse, Conference Summary, 2001: Workshop on Clinical Consequences of Marijuana

Institute of Medicine Report, 2000: Marijuana As Medicine?: The Science Beyond the Controversy

Institute of Medicine Report, 1999: Marijuana and Medicine: Assessing the Science Base

The United Kingdom Parliament, House of Lords, Select Committee on Science & Technology, Ninth Report, November 4,1998, Cannabis: The Scientific & Medical Evidence

National Institutes of Health, Expert Panel Report, 1997: Workshop on the Medical Utility of Marijuana

The Canadian Consortium for the Investigation of Cannabinoids in Human Therapeutics (CCIC)
A Summary of Research Abstracts - updated monthly

Igor Grant, MD

Introduction/Overview
CMCR Symposium, June 2018


Ziva Cooper, PhD

Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018


Iain McGregor, PhD

Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018


Thomas Marcotte, PhD

Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018


Alan Budney, PhD

Medicinal cannabis / legalization and the development of cannabis use problems
CMCR Symposium, June 2018


Copyright © 2018 CENTER FOR MEDICINAL CANNABIS RESEARCH. | University of California, San Diego
cmcr@ucsd.edu | HNRP |